Aaron Ellenbogen, DO
Neurology · Farmington Hills, MINPI 1962472241
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,211,381 of the $1,562,747 with a category attached, or 77.5%. 59 manufacturers reported payments, led by AbbVie at 48.3% of the total. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,879 payments — averaging $831.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$755K
- MDD US Operations, LLC$276K
- Ipsen Biopharmaceuticals, Inc$158K
- Acorda Therapeutics, Inc$127K
- Teva Pharmaceuticals USA, Inc.$104K
- Kyowa Kirin, Inc.$42K
- plus $101K from 53 others
Across 1,079 payments — averaging $12,176 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.1M
- Eli Lilly$1.9M
- Biogen$1.5M
- Roche TCRC, Inc.$1.2M
- Astrazeneca UK Limited$1.1M
- H. Lundbeck A S$840K
- plus $4.3M from 21 others
What the payments were for
- Consulting fees$208,33313%
- Speaking & faculty fees$1,211,38178%
- Travel & lodging$102,1967%
- Food & beverage$30,6882%
- Education$10,1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$639,462
- DYSPORT$164,747
- INBRIJA$121,659
- GOCOVRI$117,456
- APOKYN$93,287
- UBRELVY$77,456
- AUSTEDO$62,567
- NOURIANZ$41,323
- Austedo XR$39,211
- QULIPTA$23,810
- MYOBLOC$16,120
- CREXONT$11,884
- Horizant$7,766
- Xadago$7,474
- NURTEC ODT$7,365
- NORTHERA$2,000
- NUPLAZID$1,050
- INFINITY$519
- ONGENTYS$290
- Infinity DBS Pulse Generators$282
How this compares
$1,562,747 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 52 | $592,283 |
| ApokynApomorphine Hcl | 20 | $526,320 |
| NuplazidPimavanserin Tartrate | 96 | $474,877 |
| GocovriAmantadine Hcl | 106 | $391,544 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 52 | $323,134 |
| RytaryCarbidopa/Levodopa | 152 | $240,952 |
| AustedoDeutetrabenazine | 23 | $218,834 |
| Avonex (4 Pack)Interferon Beta-1a | 25 | $213,347 |
| IngrezzaValbenazine Tosylate | 21 | $162,279 |
| InbrijaLevodopa | 33 | $158,495 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,032 | $59,430 |
| NourianzIstradefylline | 20 | $49,222 |
| NeuproRotigotine | 32 | $33,683 |
| Teriflunomide | 13 | $31,682 |
| Emgality PenGalcanezumab-Gnlm | 26 | $30,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $103,544 | $811,11775 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,174 | $474,87796 claims |
| MDD US Operations, LLCGocovri | $276,046 | $391,544106 claims |
| PfizerOctagam | $62 | $323,13452 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $12,647 | $250,979165 claims |
| BiogenAvonex (4 Pack) | $59 | $213,34725 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $333 | $188,29148 claims |
| Acorda Therapeutics, IncInbrija | $126,897 | $158,49533 claims |
| UCB, Inc.Neupro, Briviact | $116 | $60,09650 claims |
| Kyowa Kirin, Inc.Nourianz | $41,743 | $49,22220 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $3,509 | $20,21811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Farmington Hills
- Richard TroschFarmington Hills$1.2M
- Martin BelkinFarmington Hills$712K
- Yang Mao DraayerFarmington Hills$372K
- Lauren AymenFarmington Hills$349K
- Daniel SingerFarmington Hills$306K
- Mark KachadurianFarmington Hills$258K
- Mark SilvermanFarmington Hills$225K
- Jonathan FellowsFarmington Hills$164K
- William BoudourisFarmington Hills$152K
- Nader WarraFarmington Hills$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.